Chemotherapy: Adjuvant and Neoadjuvant Approaches

Rectal Cancer ◽  
2010 ◽  
pp. 175-187
Author(s):  
Rachel Wong ◽  
David Cunningham ◽  
Ian Chua
Keyword(s):  
Chemotherapy Adjuvant

International tailored chemotherapy adjuvant trial: ITACA trial.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e17514-e17514 ◽  
Author(s):  
S. Novello ◽  
G. Scagliotti ◽  
V. Torri ◽  
V. Monica ◽  
M. Papotti ◽  
...  
Keyword(s):  
Adjuvant Trial ◽  
Chemotherapy Adjuvant

Surgical resection including peri-operative chemotherapy (adjuvant and neoadjuvant)

2003 ◽  
Vol 1 (6) ◽  
pp. 181-187 ◽  
Author(s):  
Bernard Nordlinger ◽  
Stéphane Benoist
Keyword(s):  
Surgical Resection ◽  
Chemotherapy Adjuvant

scholarly journals Systemic Chemotherapy for Urothelial Cancer – How to Select Systemic Therapy in Bladder Cancer

2017 ◽  
Vol 13 (02) ◽  
pp. 134 ◽  
Author(s):  
Ioannis Dimitriadis ◽  
Aristotelis Bamias ◽  
◽  
Keyword(s):  
Bladder Cancer ◽  
Adjuvant Chemotherapy ◽  
Disease Management ◽  
Systemic Therapy ◽  
Survival Benefit ◽  
Systemic Chemotherapy ◽  
Urothelial Cancer ◽  
Advanced Disease ◽  
Early Disease ◽  
Chemotherapy Adjuvant

Urothelial cancer (UC) has long been recognised as a chemosensitive disease, and systemic chemotherapy plays a crucial role in the management of localised and advanced disease. Unfortunately, there has been a paucity of progress during the last 15 years in this area. Neoadjuvant use of cisplatin-based combinations has shown survival benefit and together with radical cystectomy should constitute the cornerstone of early disease management. Most importantly, Galsky criteria concerning fitness for cisplatin provide a useful tool for clinicians, in order to select patients with substantial benefit from cisplatin-based chemotherapy. Adjuvant chemotherapy may be useful in selected cases, but its wide implementation has to be proved. Recently, the advent of modern immunotherapy seems to offer new effective choices for patients with advanced UC.

scholarly journals PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results

2021 ◽  
Vol 16 (3) ◽  
pp. S58-S59
Author(s):  
S. Novello ◽  
V. Monica ◽  
M. Serke ◽  
C. Grohe ◽  
A. Meyer ◽  
...  
Keyword(s):  
Adjuvant Trial ◽  
Chemotherapy Adjuvant

scholarly journals CHEMOTHERAPY AND HORMONE THERAPY FOR BREAST CANCER AND COMPLICATIONS

2020 ◽  
Vol 4 (6) ◽  
Author(s):  
Seema Devi ◽  
Yogesh Kumar Sharma
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Hormone Therapy ◽  
Chemotherapeutic Agents ◽  
Treatment Modalities ◽  
Mental Function ◽  
Advanced Stages ◽  
Cardiovascular Functions ◽  
Chemotherapy Adjuvant

Breast cancer is second leading cause of death in women. Treatment modalities for breast cancer optimized according to stage at which the cancer is diagnosed. Chemotherapy, hormone therapy   and targeted therapies are used for the treatment of advanced stages of disease. The aim of therapy different like to enhancing the curative rate in adjuvant therapy, reduce symptoms or  improve quality of life in metastatic diseases, reduce the chances of the cancer coming Back. The complications of therapy including mental function; cardiovascular functions; neuromusculoskeletal and movement related functions and structures functions of hematological immunological and respiratory system etc. The benefits of chemotherapy are limited and relative compared to the risk factors. Chemotherapeutic agents use in treatment of breast cancer such as taxanes (docetaxel and paclitaxel), tamoxifen , vincristine, cyclophosphamide, trastuzumab etc. Keyword: breast cancer, hormone therapy, targeted therapy, chemotherapy, adjuvant therapy.

scholarly journals The Secretome of Human Neonatal Mesenchymal Stem Cells Modulates Doxorubicin-Induced Cytotoxicity: Impact in Non-Tumor Cells

2021 ◽  
Vol 22 (23) ◽  
pp. 13072
Author(s):  
Ana S. Serras ◽  
Sérgio P. Camões ◽  
Bernardo Antunes ◽  
Vera M. Costa ◽  
Flávio Dionísio ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Proteomic Analysis ◽  
Underlying Mechanism ◽  
Breast Epithelial Cells ◽  
Malignant Breast ◽  
Breast Cells ◽  
Potential Use ◽  
Target Side ◽  
Chemotherapy Adjuvant ◽  
Target Effects

Doxorubicin (Dox) is one of the most widely used treatments for breast cancer, although limited by the well-documented cardiotoxicity and other off-target effects. Mesenchymal stem cell (MSC) secretome has shown immunomodulatory and regenerative properties, further potentiated under 3D conditions. This work aimed to uncover the effect of the MSC-derived secretome from 3D (CM3D) or 2D (CM2D) cultures, in human malignant breast cells (MDA-MB-231), non-tumor breast epithelial cells (MCF10A) and differentiated AC16 cardiomyocytes, co-treated with Dox. A comprehensive proteomic analysis of CM3D/CM2D was also performed to unravel the underlying mechanism. CM3D/CM2D co-incubation with Dox revealed no significant differences in MDA-MB-231 viability when compared to Dox alone, whereas MCF10A and AC16 viability was consistently improved in Dox+CM3D-treated cells. Moreover, neither CM2D nor CM3D affected Dox anti-migratory and anti-invasive effects in MDA-MB-231. Notably, Ge-LC-MS/MS proteomic analysis revealed that CM3D displayed protective features that might be linked to the regulation of cell proliferation (CAPN1, CST1, LAMC2, RANBP3), migration (CCN3, MMP8, PDCD5), invasion (TIMP1/2), oxidative stress (COX6B1, AIFM1, CD9, GSR) and inflammation (CCN3, ANXA5, CDH13, GDF15). Overall, CM3D decreased Dox-induced cytotoxicity in non-tumor cells, without compromising Dox chemotherapeutic profile in malignant cells, suggesting its potential use as a chemotherapy adjuvant to reduce off-target side effects.

Sign in / Sign up

Export Citation Format

Share Document